Compare AbbVie Inc (ABBV) vs Blackrock Inc (BLK) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

BlackRock (BLK) trades at $1,009.43, up 1.38% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $12.53 exceeding expectations. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights expansion into Nasdaq-100 ETFs and Bitcoin ETF offerings, positioning for growth in private markets and AI-driven demand.

Outlook remains positive with a consensus price target of $1,260, reflecting 25% upside. Key risks include volatile cash flows and competitive pressures in ETF markets. Institutional sentiment is strongly bullish, with 76% of analysts rating Buy. Earnings on July 15 will be critical for sustaining momentum.